Floatz logo

qt-219cx

Multi-Drug Resistant Nephrotic Syndrome

The Children's Hospital of Zhejiang University School of MedicineCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the Multi-Drug Resistant Nephrotic Syndrome cohort.

Asset / SponsorPhaseRating
Ucar T-Cell
The Children's Hospital of Zhejiang University School of Medicine
Phase 1CCC
RD06-05 CART Cell
The Children's Hospital of Zhejiang University School of Medicine
Early Phase 1C

Same molecule, other indications

qt-219cx is also rated in:

systemic lupus erythematosusDormant
C
Indicative ·
39 / 100
View asset →
IgA glomerulonephritisDormant
C
Indicative ·
39 / 100
View asset →
systemic sclerosisDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →